Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MBRX

Moleculin Biotech Inc

Mar 20 • 04:00PM ET

1.09

Dollar change +0.05
Percentage change 4.81	%

Healthcare • Biotechnology • USA • NASD

Peers: TGTX FATE AFMD KPTI AVIR ADAP IMMP XFOR BYSI HOOK

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.69	Insider Own	0.84%	Shs Outstand	13.30M	Perf Week	-6.03%
Market Cap	14.49M	Forward P/E	-	EPS next Y	-4.05	Insider Trans	0.00%	Shs Float	13.19M	Perf Month	-38.42%
Income	-30.15M	PEG	-	EPS next Q	-1.29	Inst Own	3.49%	Short Float	8.20%	Perf Quarter	-50.23%
Sales	0.00M	P/S	-	EPS this Y	49.24%	Inst Trans	2.67%	Short Ratio	0.19	Perf Half Y	-53.42%
Book/sh	2.49	P/B	0.44	EPS next Y	47.06%	ROA	-95.84%	Short Interest	1.08M	Perf Year	-86.79%
Cash/sh	0.71	P/C	1.54	EPS next 5Y	32.38%	ROE	-141.49%	52W Range	0.40 - 7.80	Perf YTD	-35.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.25%	ROI	-383.15%	52W High	-86.03%	Beta	2.18
Dividend TTM	-	Quick Ratio	2.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	174.21%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	2.08	EPS Y/Y TTM	13.52%	Oper. Margin	-	RSI (14)	44.77	Volatility	9.17% 15.80%
Employees	18	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.67	Target Price	18.00
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-1.04%	Payout	-	Rel Volume	0.08	Prev Close	1.04
Sales Surprise	-	EPS Surprise	-16.80%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	5.80M	Price	1.09
SMA20	-6.48%	SMA50	-19.67%	SMA200	-55.51%	Trades		Volume	451,567	Change	4.81%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform	$14

Mar-19-25 08:05AM	Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast (GlobeNewswire)
Mar-11-25 08:45AM	Moleculin Biotech, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (PR Newswire)
Mar-10-25 08:45AM	Moleculin to Present at the 37th Annual ROTH Conference (PR Newswire)
Mar-06-25 08:30AM	Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity (PR Newswire) -5.17%
Mar-03-25 08:30AM	Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium (PR Newswire) -10.85%
12:35PM	Loading…
Feb-25-25 12:35PM	Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) +20.56%
Feb-13-25 01:19PM	Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? (Benzinga) +202.38%
01:05PM	Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds (PR Newswire)
09:25AM	Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) (PR Newswire)
Feb-12-25 10:25AM	Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine (Clinical Trials Arena) -17.24%
Feb-11-25 08:40AM	Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial (PR Newswire) -27.91%
Jan-27-25 08:30AM	Moleculin Participates in Virtual Investor 'What This Means' Segment (PR Newswire)
Jan-08-25 08:30AM	Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 and 2026 (PR Newswire)
08:30AM	Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 (PR Newswire)
Dec-11-24 08:00AM	Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model (PR Newswire) +14.72%
08:15AM	Loading…
Nov-18-24 08:15AM	New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML (PR Newswire) -7.01%
Nov-14-24 08:15AM	Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 (PR Newswire) +23.11%
Nov-12-24 10:59PM	Moleculin Biotech Reports Financial Highlights and Future Plans (TipRanks) +5.18%
08:00AM	Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) (PR Newswire)
Nov-11-24 11:19PM	Q3 2024 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
07:05AM	Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-24 09:00AM	Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast (PR Newswire)
Nov-04-24 08:30AM	Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin (PR Newswire)
Oct-18-24 08:57AM	Moleculin Biotech Highlights Annamycins AML Treatment Potential (TipRanks) +9.53%
Oct-17-24 08:40AM	Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available (PR Newswire)
Oct-09-24 05:02PM	Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... (GuruFocus.com)
Oct-07-24 08:30AM	Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 (PR Newswire) +6.36%
Oct-04-24 09:00AM	Moleculin to Present at Two Upcoming Investor Conferences (PR Newswire)
Sep-23-24 08:00AM	Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma (PR Newswire) +14.35%
Sep-16-24 08:30AM	Moleculin Participates in Virtual Investor 'What this Means' Segment (PR Newswire)
08:15AM	Loading…
Sep-09-24 08:15AM	Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma (PR Newswire)
Sep-03-24 09:15AM	Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-26-24 08:30AM	Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (PR Newswire) +6.69%
Aug-19-24 04:05PM	Moleculin Announces Closing of up to $16.5 Million Public Offering (PR Newswire) +7.08%
Aug-16-24 08:00AM	Moleculin Announces Pricing of up to $16.5 Million Public Offering (PR Newswire) +9.42%
Aug-14-24 08:05AM	Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +6.38%
Aug-05-24 09:05AM	Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET (PR Newswire) -6.95%
Aug-01-24 08:30AM	Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial (PR Newswire) -27.94%
Jul-10-24 08:30AM	Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML (PR Newswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 08:00AM	Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial (PR Newswire)
Jun-12-24 09:00AM	Moleculin to Present at the Virtual Investor Pitch Conference (PR Newswire)
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
Jun-05-24 08:55AM	Moleculin to Participate in the Virtual Investor Lunch Break Series (PR Newswire) +7.95%
May-16-24 08:32AM	Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress (PR Newswire)
06:22AM	Moleculin begins NIH-funded Phase II glioblastoma treatment trial (Clinical Trials Arena)
May-15-24 08:38AM	Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) (PR Newswire)
May-14-24 03:00AM	Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
May-13-24 07:30AM	Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-10-24 09:52PM	MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:30AM	Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin (PR Newswire)
May-08-24 08:45AM	Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast (PR Newswire) -7.66%
May-07-24 08:55AM	Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data (PR Newswire)
May-02-24 09:00AM	Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 (PR Newswire)
May-01-24 08:50AM	Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin (PR Newswire)
Apr-25-24 09:45AM	Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor 'What This Means' Segment Hosted by JTC Team (ACCESSWIRE)
Apr-18-24 08:30AM	European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) (PR Newswire) +5.69%
Apr-10-24 08:30AM	Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties (PR Newswire)
Mar-28-24 10:45AM	Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference (PR Newswire) +6.68%
Mar-27-24 09:25AM	Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity (PR Newswire) +18.38%
09:05AM	Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML (PR Newswire)
Mar-26-24 08:36AM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript (Insider Monkey) -10.86%
Mar-25-24 07:30AM	Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial (PR Newswire) -7.97%
Mar-22-24 08:52PM	MBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023 (InvestorPlace) -13.96%
05:31PM	Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results (GuruFocus.com)
04:05PM	Moleculin Reports Full Year 2023 Financial Results (PR Newswire)
Mar-20-24 07:30AM	Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast (PR Newswire) -19.70%
Mar-19-24 04:30PM	Moleculin Announces Reverse Stock Split (PR Newswire)
Mar-12-24 09:05AM	Moleculin to Present at the 36th Annual ROTH Conference (PR Newswire) -11.22%
Jan-24-24 08:50AM	Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 (PR Newswire) +11.08%
Dec-20-23 09:16PM	Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market (PR Newswire)
Dec-11-23 08:50AM	Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting (PR Newswire) -8.07%
Nov-14-23 01:46PM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:29AM	Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies (Zacks)
Nov-13-23 08:05AM	Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months (PR Newswire) +6.70%
08:00AM	Moleculin Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-07-23 08:45AM	Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast (PR Newswire) -5.53%
Nov-06-23 08:35AM	Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases (PR Newswire) +14.97%
Oct-24-23 07:45AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -5.91%
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE)
Oct-11-23 09:05AM	Moleculin to Participate in the Virtual Investor Ask the CEO Conference (PR Newswire) +5.58%
Oct-02-23 08:40AM	Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) (PR Newswire)
Sep-22-23 07:58AM	Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up (Zacks) -7.14%
Sep-21-23 08:50AM	Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107) (PR Newswire) +9.95%
Sep-18-23 08:40AM	Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin (PR Newswire)
Sep-14-23 08:35AM	Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (PR Newswire)
Sep-05-23 08:35AM	Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-12-23 12:16AM	Q2 2023 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-11-23 06:45AM	Moleculin Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-10-23 04:05PM	Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones (PR Newswire)
Aug-07-23 08:40AM	Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling (PR Newswire)
Aug-03-23 08:45AM	Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast (PR Newswire)
Jul-13-23 08:40AM	Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) (PR Newswire) +17.72%
Jul-06-23 08:45AM	Moleculin to Participate in the Virtual Investor Summer Spotlight Series (PR Newswire)
Jun-13-23 08:35AM	Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (PR Newswire)
May-30-23 09:05AM	Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023 (PR Newswire) +7.72%
May-12-23 11:15AM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2023 Earnings Call Transcript (Insider Monkey) -11.26%
May-11-23 08:04AM	MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates (InvestorPlace)
07:05AM	Moleculin Reports First Quarter 2023 Financial Results (PR Newswire)
May-10-23 04:05PM	Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones (PR Newswire)

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBRX

Moleculin Biotech Inc

Upgrade your FINVIZ experience